Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program ...Middle East

PR Newswire - News
Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies Synaffix to receive up to $150m in upfront and milestone payments plus royalties AMSTERDAM, SAN FRANCISCO, HOUSTON and SINGAPORE, Jan. 4, 2023 /PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology...

Read More Details
Finally We wish PressBee provided you with enough information of ( Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program )

Apple Storegoogle play

Also on site :